There were two prevailing topics that dominated this year’s 340B Coalition Winter Conference: mega-guidance and 340B entity audits. While these terms are not mutually exclusive, they each received significant airtime throughout the conference. The mystery of mega-guidance According to 340B Health, mega-guidance (aka omnibus guidance) is a ruling designed to be a ‘one-stop-shop’ of 340B-related […]
February 29, 2016 - Curant President and CEO, Patrick Dunham, with Curant Senior Director of Pharmacy, David Carver, in Becker's Healthcare - Population health has always seemed like a unicorn to me. Every day I witness exactly what is required to positively impact outcomes for patients with chronic conditions. There is no silver bullet, no patient […]
The increase of specialty drug costs is something that cannot be denied or ignored. According to a study done by the Kaiser Family Foundation and Truven Health Analytics, prescription drug spending accounts for 10% of the national spending on healthcare. The percentage is even higher for self-insured employers. Let’s talk about the two consequences, one […]
February 22, 2016 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - According to a November 2015 report from The Pew Charitable Trusts, Specialty Drugs and Health Care Costs, in 2014, less than 1% of all prescriptions were written for specialty drugs, yet they accounted for approximately 32% of total drug expenditures. And the […]
Medication is getting pricier. We know the facts – the Kaiser Family Foundation and Truven Health Analytics calculate prescription drug spending at 10% of the total national health spend. Want to hear an even more shocking statistic? Drug spending alone in employer health plans tops out at a whopping 19% of total spend. There is […]
February 9, 2016 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - The meteoric rise of specialty drug cost has been well-documented and appropriately lambasted, at least in some circumstances. According to a recent report by the Kaiser Family Foundation and Truven Health Analytics, prescription drug spending accounts for 10% of national spending on […]
Every winter 340B Health brings key healthcare stakeholders together to discuss new 340B program developments, brainstorm and network at the 340B Coalition Winter Conference. This event provides a terrific forum for education, discussion and insight into what’s working well with the program and where there are opportunities for improvement. As a leader in personalized medication […]
February 2, 2016 - Curant Health COO, Marc O'Connor, in Managed Healthcare Executive - The continuous increase in medication spending, especially spending related to specialty drug costs, has been well-documented and appropriately lambasted in some circumstances. According to a report by the Kaiser Family Foundation and Truven Health Analytics, prescription drug spending accounts for 10% […]
January 29, 2016 – Atlanta, Georgia – Curant Health congratulates David Carver, Pharm. D., on his promotion to Senior Director of Pharmacy Operations. Carver joined the Curant Health team in 2012 with over 20 years’ experience across multiple pharmacy and specialty pharmacy management disciplines. Curant Health President and CEO, Patrick Dunham, notes “David has made a […]
The J.P. Morgan Healthcare Conference 2016 will arguably rank as the largest business of healthcare conference scheduled anywhere in the world this year. Although there have already been numerous reviews and takeaways regarding the conference, I’d like to share with you the top three topics absent from this year's conference. What is the most needed that we didn’t […]
